Aggressive Behavior in Children and Adolescents-Reference-Cited by-同舟云学术

Aggressive Behavior in Children and Adolescents

Published:2011-08-01 Issue:8 Volume:32 Page:325-332
ISSN:0191-9601
Container-title:Pediatrics In Review
language:en
Short-container-title:

Author:

Zahrt Dawn M.¹,Melzer-Lange Marlene D.²

Affiliation:

1. Assistant Professor of Pediatrics, Section of Child Development, Pediatric Psychologist, Children's Hospital of Wisconsin, Milwaukee, WI.

2. Professor of Pediatrics, Section of Emergency Medicine, Medical College of Wisconsin, Medical Director, Emergency Department, Children's Hospital of Wisconsin, Milwaukee, WI.

Publisher

American Academy of Pediatrics (AAP)

Subject

Pediatrics, Perinatology and Child Health

Link

https://publications.aap.org/pediatricsinreview/article-pdf/32/8/325/996356/zpx00811000325.pdf

Reference8 articles.

1. Importance of early neglect for childhood aggression;Kotch;Pediatrics,2008

2. Longitudinal relations between children's exposure to television violence and their aggressive and violent behavior in young adulthood: 1977–1992;Huesmann;Dev Psychol,2003

3. The role of violent media preference in cumulative developmental risk for violence and general aggression;Boxer;J Youth Adolesc,2009

4. Short-term and long-term effects of violent media on aggression in children and adults;Bushman;Arch Pediatr Adolesc Med,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gender differences in behavioral and emotional problems among school children and adolescents in China: National survey findings from a comparative network perspective;Journal of Affective Disorders;2024-09

2. ADVERSE CHILDHOOD EXPERIENCES AND THEIR RELATIVITY TO AGGRESSION OF YOUNG ADULTS IN MALITA, DAVAO OCCIDENTAL PHILIPPINES;International Journal of Legal Studies ( IJOLS );2024-07-19

3. Oppositional Defiant Disorder: Clinical Considerations and When to Worry;Pediatrics in Review;2024-03-01

4. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial;American Journal of Respiratory and Critical Care Medicine;2023-07-01

5. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele;American Journal of Respiratory and Critical Care Medicine;2023-07-01